PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223.
Status:
Unknown status
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
PRORADIUM is a prospective multicentre observational study in metastatic Castration-Resistant
Prostate Cancer (mCRPC), designed to explore prognostic biomarkers in patients undergoing
treatment with radium-223.
Details
Lead Sponsor:
Centro Nacional de Investigaciones Oncologicas CARLOS III
Collaborator:
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud